MK-0777 is a selective GABA-A α2/α3 subunit agonist originally developed for cognitive impairment in schizophrenia. It improves working memory and cognitive flexibility without the sedation and motor impairment of non-selective benzodiazepines.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
MK-0777 (sometimes noted as MK-777 in research contexts) is a selective benzodiazepine-site agonist that binds preferentially to GABA-A receptor subtypes containing the α2 and α3 subunits, while avoiding the α1 subunit that mediates sedation, amnesia, and motor impairment. This subtype selectivity was achieved to produce the cognitive and anxiolytic benefits of benzodiazepines — which are well documented but obscured by their universal GABA-A activation — without the sedating and cognitively impairing α1-mediated effects that make conventional benzodiazepines counterproductive in cognitive enhancement contexts.
Mechanism of Action
GABA-A receptors are the primary inhibitory receptors in the CNS, and different subunit compositions determine their functional roles. α1-containing receptors mediate sedation, hypnosis, and amnesia. α2-containing receptors mediate anxiolysis and cognitive benefits including working memory improvement. α3-containing receptors contribute to anxiolysis and motor coordination. MK-0777 selectively activates α2 and α3 subtypes, producing anxiolytic and pro-cognitive effects through selective inhibitory modulation of prefrontal cortex and hippocampal circuits without the broad CNS depression of non-selective benzodiazepines. The prefrontal cortex, which is critical for working memory and executive function, contains high concentrations of α2-subunit GABA-A receptors — making them a precise target for cognitive enhancement.
Key Research
Phase 2 clinical trials at Merck investigated MK-0777 for cognitive impairment in schizophrenia. A published Phase 2b study (N=60) demonstrated statistically significant improvement on multiple cognitive domains including spatial working memory, attention, and processing speed at 4 weeks compared to placebo. The effect was independent of antipsychotic medication. Further development was not pursued to Phase 3 for business reasons. Additional research examined MK-0777 in age-related cognitive decline and post-operative cognitive dysfunction. The compound demonstrated it was possible to dissociate benzodiazepine anxiolytic effects from sedation, establishing proof-of-concept for subtype-selective GABA-A modulation as a cognitive enhancement strategy.
1–8 mg orally once or twice daily (clinical trial range)
Half-Life
~4–8 hours
Clinical research doses ranged from 1–8 mg orally once or twice daily. The optimal dose for cognitive effects without residual sedation appeared to be in the 4 mg range based on Phase 2 data. Because it has α2/α3 selectivity but not complete α1 avoidance, some sedation at higher doses is possible — start low and titrate. Due to GABA-A receptor modulation, tolerance to the anxiolytic effects (but not necessarily cognitive effects) can develop with continuous daily use — cycling or intermittent dosing is advisable.
Cognitive Research Protocol: MK-0777 4 mg orally once daily in the morning for 6–8 weeks, with 4-week breaks to reduce tolerance. Combine with Semax 200 mcg intranasally for BDNF-driven neuroplasticity alongside GABAergic cognitive modulation. Anxiety and Cognition Stack: MK-0777 2–4 mg + Selank 250 mcg intranasally for complementary GABA modulation with serotonergic anxiolytic support.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
The selective subunit profile means sedation is significantly reduced compared to non-selective benzodiazepines, but not eliminated at higher doses — cognitive impairment at doses above the therapeutic window can occur. Tolerance to anxiolytic effects can develop with continuous use — this is less a concern for cognitive applications but warrants cycling. Physical dependence risk is theoretically lower than non-selective benzodiazepines due to reduced α1 engagement, but has not been rigorously studied in long-term research. Dizziness and mild drowsiness at initiation are the most commonly reported effects. As with all GABA-A modulators, caution with alcohol and CNS depressants. Not suitable for individuals with a history of benzodiazepine dependence.
Storage & Handling
Oral tablets or capsules — store at room temperature, away from light and moisture. Standard shelf life. Not widely commercially available — typically available as a research chemical. Store per specific formulation guidelines.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
